Related Experiment Video
Updated: Aug 5, 2026

Detection of Tissue-resident Bacteria in Bladder Biopsies by 16S rRNA Fluorescence In Situ Hybridization
Published on: October 18, 2019
[Use of sparfloxacin (Sparflo) in treating complicated urologic infections]
Abstract:
The authors review the effectiveness of a novel fluoroquinolone drug sparfloxacine (Sparflo, Dr. Reddy's Laboratories) in the treatment of patients with complicated forms of pyelonephritis and prostatitis. Both gramnegative and grampositive agents causing complicated urologic infections were highly sensitive to sparfloxacine: Enterobacter spp.--40.8%, Pseudomonas aeruginosa--38.5%, Proteus spp.--42.6%, E. coli--91.4%, Staphylococcus spp.--80.0%, Enterococcus faecalis--21.4%. Sparfloxacine was used in the treatment of 43 patients with complicated pyelonephritis and prostatitis. The complicating factors were the following: urolithiasis, renal anomalies, hydronephrotic transformation, nephroptosis, benign prostatic hyperplasia. Clinical response reached 83.7%; microbiological--78.7%. Thus, sparfloxacin has a wide spectrum of antibacterial activity and can be effectively used in patients with complicated infections of the urinary tract.
Insights
This study shows that sparfloxacin is effective for treating complicated urinary tract infections like pyelonephritis and prostatitis. It demonstrates broad-spectrum activity against common bacterial pathogens, offering a viable treatment option.
Area of Science:
- Pharmacology
- Infectious Diseases
- Urology
Context:
- Complicated urinary tract infections (UTIs) pose significant treatment challenges.
- Pyelonephritis and prostatitis often involve complex etiological factors and resistant pathogens.
Purpose:
- To evaluate the efficacy of sparfloxacin, a novel fluoroquinolone, in treating complicated pyelonephritis and prostatitis.
- To assess the in vitro susceptibility of uropathogens to sparfloxacin.
Summary:
- Sparfloxacin exhibited high in vitro activity against key Gram-negative (e.g., E. coli, P. aeruginosa) and Gram-positive (e.g., Staphylococcus spp.) bacteria implicated in complicated UTIs.
- In a clinical trial of 43 patients with complicated pyelonephritis and prostatitis (due to urolithiasis, renal anomalies, etc.), sparfloxacin achieved an 83.7% clinical response and a 78.7% microbiological response.
Impact:
- Sparfloxacin demonstrates broad-spectrum antibacterial activity.
- The drug is a potentially effective therapeutic agent for complicated urologic infections.
Related Concept Videos
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urinary Tract Infection IV: Nursing Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Urine Studies II: Urine Culture and Sensitivity Test

